The author conducted a survey of medical oncologists, otolaryngologists, head and neck surgeons, and ENT physicians in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into SCCHN diagnosis, patient segmentation, current prescribing patterns, factors influencing decision-making, and key treatment challenges.
This module is accompanied by a datapack showing treatment trees that provide an approximation of the potential patient populations at each step in the treatment algorithm and indicate estimated patient numbers; they should not be interpreted as showing exact patient numbers.
The standard of care for early-stage SCCHN is centered around surgical resection. The majority of Stage I and Stage II patients across the US, Japan, and five major EU markets receive surgery as a part of their treatment.
The majority of patients who present with Stage III disease are treated with a multi-modal approach. The combination of surgery, radiotherapy, and systemic therapy is the primary treatment option for these patients. However, concurrent chemoradiation without surgery is the preferred treatment for patients who are unable or unwilling to undergo surgery, as well as those with unresectable disease.
The use of systemic therapy increases with disease stage. While treatment for early-stage disease is based on surgical resection with curative intent, late-stage, recurrent, or metastatic disease is treated primarily with chemotherapy.
The author conducted a survey of 211 medical oncologists, otolaryngologists, ENT physicians, and head and neck surgeons in the US, Japan, and five major EU markets on their treatment choices for SCCHN.
Key Topics Covered:
FORECAST: HEAD AND NECK CANCER
- Market Definition and Methodology
- Erbitux (cetuximab)
- Gilotrif (afatinib)
- Javlor (vinflunine ditartrate)
- Keytruda (pembrolizumab)
- Opdivo (nivolumab)
TS-1 (gimeracil/oteracil potassium/tegafur)
TREATMENT: HEAD AND NECK CANCER
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: HEAD AND NECK CANCER
- Disease Background
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: HEAD AND NECK CANCER
- Product Overview
- Product profile: Erbitux
PIPELINE: HEAD AND NECK CANCER
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Comparator Therapy
- Product profile (late stage): Gilotrif
- Product profile (late stage): Javlor
- Product profile (late stage): Keytruda
- Product profile (late stage): Multikine
- Product profile (late stage): Opdivo
- Product profile (late stage): Reolysin
- Product profile (late stage): durvalumab
For more information about this report visit https://www.researchandmarkets.com/research/w7jgng/head_and_neck?w=4